Thermo Fisher to sell Progen primary antibodies

By The Science Advisory Board staff writers

April 30, 2021 -- Gene therapy tools manufacturer Progen Biotechnik has signed a nonexclusive distribution agreement with Thermo Fisher Scientific.

Under the agreement, Thermo Fisher will offer a choice of 371 primary antibodies globally. Among them are top-selling products in biomedical research and development, such as lipid metabolism, cytoskeleton, cell adhesion, and oncology. The antibodies will be available with full service and support from Thermo Fisher.

Progen's portfolio includes over 1,000 primary and secondary antibodies for basic and applied life science research.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here